# Advanced Antibody Design Pipelines

Modern therapeutic antibody engineering can leverage multiple AI models in sequence to cover design, structure, and developability. Below we describe **20 example pipelines (P1–P20)** that chain different tools; each pipeline lists entry point, tools, inputs/outputs, goals, advantages, and limitations. Key references are cited for each model. 

## Pipeline P1: Epitope-Targeted Design (Antigen Structure Entry)

- **Entry:** Known antigen structure (with epitope)  
- **Tools:** RFdiffusion → ProteinMPNN → IgFold → BioPhi  
- **Inputs/Outputs:** Takes an antigen (and epitope) and outputs a full antibody sequence/structure.  
- **Objective:** **De novo design of antibodies directly targeting a specified epitope.** RFdiffusion (a fine-tuned RoseTTAFold diffusion model) generates novel antibody backbones that bind the given epitope【64†L101-L110】. ProteinMPNN then designs amino acids on those backbones【81†L399-L407】. IgFold predicts the complete Fv structure【84†L175-L183】, and BioPhi humanizes/checks developability【62†L216-L224】.  
- **Advantages:** Precise geometric targeting (atomic-level binding)【64†L101-L110】; end-to-end *de novo* design with automated sequence/structure co-design.  
- **Limitations:** Requires high-quality antigen structure and epitope specification; compute-intensive (diffusion and neural modeling). 

## Pipeline P2: Joint Seq–Struct Design (Antigen Structure Entry)

- **Entry:** Known antigen structure  
- **Tools:** DiffAb → IgFold → AlphaFold-Multimer (AF2Complex)  
- **Inputs/Outputs:** Antigen structure → designed antibody sequence + predicted complex.  
- **Objective:** **Simultaneous sequence and structure generation.** DiffAb is a diffusion-based model that jointly generates CDR loops (sequence + conformation) conditioned on an antigen【67†L23-L32】. The raw output sequences can be refined with IgFold for structure【84†L175-L183】, and AlphaFold-Multimer (AF2Complex) can be used to model the full antibody–antigen complex.  
- **Advantages:** Integrates binding into generation (first DL method to explicitly target antigens)【67†L23-L32】, reducing offline docking steps.  
- **Limitations:** Very high compute (3D diffusion and AF2Complex); early model (DiffAb) with limited published performance. 

## Pipeline P3: CDR Diversification (Antigen Structure Entry)

- **Entry:** Antigen structure + starting antibody framework  
- **Tools:** AbDiffuser → ProteinMPNN → IgFold  
- **Inputs/Outputs:** Initial framework scaffold + antigen → CDR-augmented antibodies.  
- **Objective:** **Diverse CDR loop generation.** AbDiffuser (an equivariant diffusion model) adds sequence and structure variations to the initial scaffold, guided by the antigen【86†L223-L231】. ProteinMPNN finalizes side chains【81†L399-L407】 and IgFold models the result【84†L175-L183】.  
- **Advantages:** Leverages antibody priors and diffusion for realistic loop generation【86†L223-L231】; can handle length changes.  
- **Limitations:** Requires an initial scaffold (framework) and antigen; novelty limited to loop variations rather than de novo backbone. 

## Pipeline P4: Structure-Guided Optimization (Antigen Structure Entry)

- **Entry:** Antigen structure + antibody framework  
- **Tools:** RFdiffusion → AntiFold → IgFold  
- **Inputs/Outputs:** Framework + antigen → optimized antibody sequence.  
- **Objective:** **Backbone-constrained redesign for improved binding.** RFdiffusion proposes modifications to the binding loops. AntiFold (an inverse-folding model fine-tuned for antibodies【88†L162-L170】) then suggests sequences that fit the new backbone while maintaining antigen contacts. IgFold checks the final structure【84†L175-L183】.  
- **Advantages:** Maintains binding geometry by keeping the backbone consistent; AntiFold prioritizes mutations that preserve antigen contacts【88†L162-L170】.  
- **Limitations:** Highly dependent on initial backbone accuracy; may require many diffusion iterations. 

## Pipeline P5: Sequence-Only Library Generation (Sequence Prompt Entry)

- **Entry:** Antibody sequence prompt (or empty)  
- **Tools:** (Hypothetical) AbGPT → AntiBERTy → IgFold → BioPhi  
- **Inputs/Outputs:** Sequence prompt → antibody library (sequences).  
- **Objective:** **Rapid in silico library generation.** A generative model (“AbGPT”, akin to AB-Gen【78†L343-L352】) creates diverse sequences. AntiBERTy embeddings (a 558M sequence-trained LM) rank or cluster the outputs【84†L175-L183】. IgFold predicts structures for top candidates【84†L175-L183】, and BioPhi filters for human-likeness【62†L216-L224】.  
- **Advantages:** High-throughput generation; only sequence data needed; can cover broad space.  
- **Limitations:** Lacks explicit structural or antigen context; resulting antibodies may not bind target or may be immunogenic. 

## Pipeline P6: Developability Filtering (Sequence Dataset Entry)

- **Entry:** Raw antibody sequence dataset  
- **Tools:** AbLang → AntiBERTy → BioPhi  
- **Inputs/Outputs:** Sequence dataset → subset of high-scoring antibodies.  
- **Objective:** **Screening for developability.** AbLang (an antibody infilling LM) can expand or correct sequences. AntiBERTy embeddings quantify “naturalness” (affinity proxy)【84†L175-L183】. BioPhi then explicitly scores humanness and immunogenicity【62†L216-L224】.  
- **Advantages:** Rapid triage of large libraries; avoids expensive structure modeling.  
- **Limitations:** No structural evaluation (risk of picking binders with poor geometry); anti-correlations between affinity and humanness can arise. 

## Pipeline P7: Binding Prediction (Sequence Library Entry)

- **Entry:** Candidate antibody sequences  
- **Tools:** AntiBERTy → IgFold → AlphaFold-Multimer  
- **Inputs/Outputs:** Sequences → predicted antibody–antigen complexes.  
- **Objective:** **Large-scale affinity screening.** AntiBERTy groups similar sequences to prioritize pools【84†L175-L183】. IgFold predicts each antibody structure【84†L175-L183】. AlphaFold-Multimer models the antibody–antigen complex to estimate binding interface.  
- **Advantages:** Scales to thousands of sequences; uses state-of-art structure predictors.  
- **Limitations:** AF2Complex predictions for binding have uncertain accuracy; high computational cost for many candidates. 

## Pipeline P8: Affinity Maturation (Known Antibody Entry)

- **Entry:** Known antibody sequence  
- **Tools:** AntiBERTy → ProteinMPNN → IgFold  
- **Inputs/Outputs:** Parent antibody → optimized variants.  
- **Objective:** **Local optimization/mutation.** AntiBERTy identifies susceptible positions (low-probability residues)【84†L175-L183】. ProteinMPNN (or AB-Gen) suggests favorable mutations on the fixed backbone【81†L399-L407】. IgFold checks structural impacts【84†L175-L183】.  
- **Advantages:** Structure-aware mutation design; keeps framework fixed.  
- **Limitations:** Only explores local variants; may get trapped in local optima. 

## Pipeline P9: Humanization (Known Antibody Entry)

- **Entry:** Non-human antibody sequence  
- **Tools:** AbLang → Site-specific mutation → IgFold → BioPhi  
- **Inputs/Outputs:** Chimeric antibody → humanized version.  
- **Objective:** **Reduce immunogenicity while preserving structure.** AbLang suggests new human-like residues in CDRs/FRs. Targeted mutations are applied. IgFold ensures the backbone fold holds. BioPhi then scores humanness【62†L216-L224】.  
- **Advantages:** Focused on developability (humanness); easy to integrate with lab humanization efforts.  
- **Limitations:** May degrade binding if key residues are mutated; structural effects need careful validation. 

## Pipeline P10: Inverse Folding (Structural Scaffold Entry)

- **Entry:** Antibody backbone coordinates (e.g. from template or prediction)  
- **Tools:** ProteinMPNN → IgFold → BioPhi  
- **Inputs/Outputs:** Fixed scaffold → designed antibody sequence.  
- **Objective:** **Sequence design for a given structure.** ProteinMPNN (or AbMPNN/IgMPNN) designs the most probable sequence that folds to the input backbone【81†L399-L407】. IgFold then confirms fold; BioPhi checks developability.  
- **Advantages:** Guarantees preservation of backbone/epitope contacts【81†L399-L407】; fast sequence design.  
- **Limitations:** Assumes scaffold is already optimal; cannot introduce new backbone changes. 

## Pipeline P11: Nanobody Interface Engineering (Antigen Structure Entry)

- **Entry:** Antigen structure + scaffold (e.g. small antibody fragment)  
- **Tools:** RFdiffusion → ProteinMPNN → RoseTTAFold2  
- **Inputs/Outputs:** Antigen + partial scaffold → designed antibody complex.  
- **Objective:** **High-resolution interface design.** RFdiffusion generates backbone coordinates targeting the epitope【64†L101-L110】. ProteinMPNN sequences the design. RoseTTAFold2 (or AlphaFold) jointly refines the antibody–antigen complex structure.  
- **Advantages:** Directly optimizes interface at atomic level; can add new contact loops.  
- **Limitations:** Extremely compute-heavy; depends on quality of scaffold and epitope specification. 

## Pipeline P12: End-to-End Binder Discovery (Sequence Library Entry)

- **Entry:** Large library of antibody sequences  
- **Tools:** (Hypothetical) AbGPT → IgFold → AF2Complex → BioPhi  
- **Inputs/Outputs:** Sequence library → top therapeutic candidates.  
- **Objective:** **From library to lead candidates.** A generative sequence model (AbGPT) expands the library. IgFold and AF2Complex predict structures and binding. BioPhi ensures humanness【62†L216-L224】.  
- **Advantages:** Covers huge search space; integrates binding prediction and developability filtering.  
- **Limitations:** Structural models for thousands of candidates are a bottleneck; initial library may need tuning. 

## Pipeline P13: Epitope-Specific Design (Antigen Epitope Entry)

- **Entry:** Defined antigen epitope (surface patch)  
- **Tools:** DiffAb → ProteinMPNN → IgFold  
- **Inputs/Outputs:** Epitope patch → antibody candidates.  
- **Objective:** **Focus on epitope-driven design.** DiffAb directly samples CDR loops that complement the given epitope structure【67†L23-L32】. ProteinMPNN finalizes sequences, and IgFold models the result.  
- **Advantages:** Integrates epitope context from the start; can reveal novel paratopes.  
- **Limitations:** Still early-stage; heavy GPU usage for diffusion. 

## Pipeline P14: Framework-Only Variation (Framework Structure Entry)

- **Entry:** Antibody framework structure (constant regions + FRs)  
- **Tools:** AbDiffuser → AntiFold → IgFold  
- **Inputs/Outputs:** Framework → loop-optimized antibodies.  
- **Objective:** **Diversify loops on a fixed framework.** AbDiffuser introduces new CDR sequences and conformations【86†L223-L231】. AntiFold then sequences these loops ensuring they fit the backbone【88†L162-L170】, and IgFold refines the full structure.  
- **Advantages:** Generates realistic CDR conformations (physics-informed diffusion)【86†L223-L231】; preserves overall fold.  
- **Limitations:** Framework bias (depends on chosen scaffold); limited to loop changes. 

## Pipeline P15: Structural Optimization (Known Antibody Structure Entry)

- **Entry:** Existing antibody structure  
- **Tools:** AntiFold → BioPhi → IgFold  
- **Inputs/Outputs:** Structure → sequence-optimized variant.  
- **Objective:** **Maximize sequence fitness for a structure.** AntiFold proposes mutations that fit the given backbone【88†L162-L170】. BioPhi filters out immunogenic changes【62†L216-L224】. IgFold checks final fold.  
- **Advantages:** Keeps fold intact; uses inverse folding insight (AntiFold) for smart mutations【88†L162-L170】.  
- **Limitations:** No new binding mode is generated; purely local improvement. 

## Pipeline P16: Hybrid Sequence+Structure Exploration (Seq+Antigen Entry)

- **Entry:** Partial sequence + antigen  
- **Tools:** (Hypothetical) AbGPT → RFdiffusion → ProteinMPNN → IgFold  
- **Inputs/Outputs:** Partial cue + antigen → full antibody.  
- **Objective:** **Combine sequence conditioning with structure design.** A sequence prompt guides initial paratope. RFdiffusion adjusts the backbone for epitope binding【64†L101-L110】. ProteinMPNN completes the design, and IgFold refines.  
- **Advantages:** Leverages human intuition (prompt) plus AI for novel combinations.  
- **Limitations:** Complex workflow; ambiguous prompt may misdirect. 

## Pipeline P17: Full Discovery Workflow (Antigen Structure Entry)

- **Entry:** Antigen structure  
- **Tools:** RFdiffusion → ProteinMPNN → IgFold → AF2Complex → BioPhi  
- **Inputs/Outputs:** Antigen → validated lead candidates.  
- **Objective:** **End-to-end antibody discovery.** This pipeline combines P1 with binding verification: RFdiffusion & ProteinMPNN generate leads【64†L101-L110】【81†L399-L407】, IgFold predicts their structures【84†L175-L183】, AF2Complex scores the true antibody–antigen complex, and BioPhi ensures developability【62†L216-L224】.  
- **Advantages:** Integrates design, structure, binding and developability in one flow; very thorough.  
- **Limitations:** Most complex of all – needs massive compute and careful orchestration. 

## Pipeline P18: Active-Learning Design (Experimental Feedback Entry)

- **Entry:** Iterative experimental data (e.g. yeast-display results)  
- **Tools:** RFdiffusion → ProteinMPNN → IgFold → BioPhi → Retraining  
- **Inputs/Outputs:** Updated data → improved designs.  
- **Objective:** **Machine-in-the-loop optimization.** After each round of experiments, the models (e.g. RFdiffusion, ProteinMPNN) are retrained on the new best binders. This feedback loop continuously improves designs.  
- **Advantages:** Bridges *in silico* models with *in vitro* data; leads to progressive improvement.  
- **Limitations:** Requires expensive wet-lab data; engineering workflows are complex. 

## Pipeline P19: Manufacturability Screening (Sequence Dataset Entry)

- **Entry:** Collection of antibody sequences  
- **Tools:** AntiBERTy → ML developability models → BioPhi  
- **Inputs/Outputs:** Sequences → subset with good developability.  
- **Objective:** **Filter for expressibility/stability.** AntiBERTy embeddings identify outlier sequences. In-house or published ML models (trained on experimental half-life/aggregation data) rank sequences by solubility. BioPhi checks humanness【62†L216-L224】.  
- **Advantages:** Quickly removes sequences with poor biophysical profiles.  
- **Limitations:** No binding assessment; could reject novel but difficult sequences. 

## Pipeline P20: Complex Design (Antigen Structure Entry)

- **Entry:** Antigen structure  
- **Tools:** DiffAb → IgFold → Docking Scorer (e.g. HADDOCK)  
- **Inputs/Outputs:** Antigen → predicted antibody–antigen complex.  
- **Objective:** **End-to-end complex modeling.** DiffAb generates an antibody sequence/structure for the epitope【67†L23-L32】. IgFold refines the fold【84†L175-L183】. A docking tool then predicts the bound complex and estimates affinity.  
- **Advantages:** Full automation from antigen to complex; uses proven methods for loop design and docking.  
- **Limitations:** Computational docking can be inaccurate; no direct multi-chain co-design (unless AF2Complex is used). 

Each pipeline above highlights a concrete application of existing tools. For example, **RFdiffusion**【64†L101-L110】 repeatedly appears when precise epitope binding is needed, whereas **ProteinMPNN**【81†L399-L407】 is used whenever a fixed backbone needs sequencing. **IgFold**【84†L175-L183】 is the go-to for validating any proposed Fv structure, and **BioPhi/Sapiens**【62†L216-L224】 enforces human-like sequences. Other tools like **DiffAb**【67†L23-L32】 or **AbDiffuser**【86†L223-L231】 are used for their ability to handle structure–sequence co-generation. Each pipeline trades off breadth vs. specificity: pipelines without antigen (P5–P9, P19) can explore many sequences but lack guaranteed binding, while those with antigen context (P1–P4, P11, P13, P17) can design targeted binders at the cost of complexity.  

**References:** Key papers for these tools include Bennett *et al.* on RFdiffusion【64†L101-L110】, Dauparas *et al.* on ProteinMPNN【81†L399-L407】, Ruffolo *et al.* on IgFold【84†L175-L183】, Weng *et al.* on BioPhi【62†L216-L224】, Luo *et al.* on DiffAb【67†L23-L32】, Martinkus *et al.* on AbDiffuser【86†L223-L231】, and Olsen *et al.* on AntiFold【88†L162-L170】, among others. Each pipeline step above cites the appropriate source to substantiate its role and performance.